Immune checkpoint inhibitors and novel immunotherapy approaches for breast cancer
M Cejuela, A Vethencourt, S Pernas - Current Oncology Reports, 2022 - Springer
Abstract Purpose of Review To critically review the existing evidence on immune checkpoint
inhibitors (ICIs) in early-stage and metastatic breast cancer and discuss emerging strategies …
inhibitors (ICIs) in early-stage and metastatic breast cancer and discuss emerging strategies …
Pathology of neoadjuvant therapy and immunotherapy testing for breast cancer
E Provenzano, AM Shaaban - Histopathology, 2023 - Wiley Online Library
Neoadjuvant chemotherapy (NACT) has become the standard of care for high‐risk breast
cancer, including triple‐negative (TNBC) and HER2‐positive disease. As a result, handling …
cancer, including triple‐negative (TNBC) and HER2‐positive disease. As a result, handling …
[HTML][HTML] CD8+ T-cell exhaustion in the tumor microenvironment of head and neck squamous cell carcinoma determines poor prognosis
Y Zhang, L Li, W Zheng, L Zhang… - Annals of Translational …, 2022 - ncbi.nlm.nih.gov
Background The occurrence of head and neck squamous cell carcinoma (HNSCC) is
closely related to the immune system. The integration of traditional treatment methods and …
closely related to the immune system. The integration of traditional treatment methods and …
The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
Y Xu, F Zuo, H Wang, J Jing, X He - Frontiers in Immunology, 2022 - frontiersin.org
Immune checkpoint blockade (ICB) therapy has evoked a prominent shift in anticancer
therapy. Durable clinical antitumor activity to ICB has been observed in patients with ovarian …
therapy. Durable clinical antitumor activity to ICB has been observed in patients with ovarian …
Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology
V Valentini, V Silvestri, A Bucalo, G Conti… - Frontiers in …, 2023 - frontiersin.org
Introduction Compared with breast cancer (BC) in women, BC in men is a rare disease with
genetic and molecular peculiarities. Therapeutic approaches for male BC (MBC) are …
genetic and molecular peculiarities. Therapeutic approaches for male BC (MBC) are …
Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy
Y Zhou, J Zhou, X Hao, H Shi, X Li, A Wang… - Breast Cancer Research …, 2023 - Springer
Purpose Breast cancer has become the leading cause of cancer mortality in women.
Although immune checkpoint inhibitors targeting programmed death-1 (PD-1) are promising …
Although immune checkpoint inhibitors targeting programmed death-1 (PD-1) are promising …
A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer
J Zhang, M Zhang, Q Tian, J Yang - Clinical and Experimental Medicine, 2023 - Springer
Triple negative breast cancer (TNBC) is the most aggressive and malignant subtype in
breast cancer. Immunotherapy is a currently promising and effective treatment for TNBC …
breast cancer. Immunotherapy is a currently promising and effective treatment for TNBC …
Neither tumor-infiltrating lymphocytes nor cytotoxic t cells predict enhanced benefit from chemotherapy in the DBCG77B Phase III clinical trial
Simple Summary Apart from the direct killing of cancer cells, cyclophosphamide-based
chemotherapy has been shown to induce an antitumor immune response, and is being used …
chemotherapy has been shown to induce an antitumor immune response, and is being used …
Characterization of the immune environment in pregnancy-associated breast cancer
Pregnancy-associated breast cancer (PrBC) is a rare and clinically challenging condition.
Specific immune mechanisms and pathways are involved in maternal–fetal tolerance and …
Specific immune mechanisms and pathways are involved in maternal–fetal tolerance and …
Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023
J Gligorov, MA Benderra, X Barthere, L de Forceville… - Bulletin du …, 2023 - Elsevier
Résumé Avec plus de 60 000 nouveaux cas de cancer du sein en France métropolitaine en
2023 et 8% de l'ensemble des décès par cancer tous sexes confondus, le cancer du sein se …
2023 et 8% de l'ensemble des décès par cancer tous sexes confondus, le cancer du sein se …